Note 8 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($) |
1 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
Jan. 31, 2017 |
May 31, 2016 |
Dec. 31, 2015 |
Mar. 31, 2015 |
Sep. 30, 2017 |
|
| Reclassification of Funds Invested | $ 200,000 | $ 200,000 | |||
| MT [Member] | |||||
| Convertible Preferred Stock, PIK Coupon, Percentage | 10.00% | ||||
| Convertible Preferred Stock, Conversion Price, Market Cap | $ 500,000,000 | ||||
| MT [Member] | Chief Executive Officer [Member] | |||||
| Payments to Acquire Businesses and Interest in Affiliates | $ 200,000 | ||||
| MT [Member] | Platinum [Member] | |||||
| Payments to Acquire Businesses and Interest in Affiliates | $ 200,000 | $ 200,000 | $ 300,000 | ||
| X | ||||||||||
- Definition Represents the market cap associated with the conversion price of convertible preferred stock. No definition available.
|
| X | ||||||||||
- Definition Represents the percentage associated with the paid-in-kind coupon for convertible preferred stock. No definition available.
|
| X | ||||||||||
- Definition Represents the reclassification of funds invested during the period. No definition available.
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|